Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 15 Jul 2022 Acquisition and disposal of own shares Read More 8 Jul 2022 Acquisition and disposal of own shares Read More 1 Jul 2022 Acquisition and disposal of own shares Read More 24 Jun 2022 Share Repurchase Program 2022 to cover UCB's Long Term Incentive Plans for employees Read More 24 Jun 2022 Disposal of own shares Read More 24 Jun 2022 UCB updates financial guidance for 2022 while maintaining 2025 financial guidance Read More Pagination First page Previous page Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
